367 related articles for article (PubMed ID: 34877641)
1. Public Health Impact and Cost-Effectiveness Analysis of Routine Infant 4CMenB Vaccination in Germany to Prevent Serogroup B Invasive Meningococcal Disease.
Scholz S; Schwarz M; Beck E; Meszaros K; Schneider M; Ultsch B; Greiner W
Infect Dis Ther; 2022 Feb; 11(1):367-387. PubMed ID: 34877641
[TBL] [Abstract][Full Text] [Related]
2. Public Health Impact and Cost-Effectiveness Analysis of 4-Component Meningococcal Serotype B Vaccination for Infants in France.
de Pouvourville G; Breau-Brunel M; Loncle-Provot V; Beck E; Gaugain L; Nachbaur G; Pribil C
Pharmacoecon Open; 2024 May; ():. PubMed ID: 38780884
[TBL] [Abstract][Full Text] [Related]
3. Modeling the public health impact of different meningococcal vaccination strategies with 4CMenB and MenACWY versus the current toddler MenACWY National Immunization Program in Chile.
Graña MG; Cavada G; Vasquez M; Shen J; Maervoet J; Klint J; Gómez JA
Hum Vaccin Immunother; 2021 Dec; 17(12):5603-5613. PubMed ID: 34890520
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness of 4CMenB Infant Vaccination in England: A Comprehensive Valuation Considering the Broad Impact of Serogroup B Invasive Meningococcal Disease.
Beck E; Klint J; Neine M; Garcia S; Meszaros K
Value Health; 2021 Jan; 24(1):91-104. PubMed ID: 33431159
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of meningococcal serogroup B disease in children after implementation of routine infant 4CMenB vaccination in England: an active, prospective, national surveillance study.
Mensah AA; Campbell H; Clark SA; Ribeiro S; Lucidarme J; Bai X; Borrow R; Ladhani SN
Lancet Child Adolesc Health; 2023 Mar; 7(3):190-198. PubMed ID: 36736341
[TBL] [Abstract][Full Text] [Related]
6. 'Be on the TEAM' Study (Teenagers Against Meningitis): protocol for a controlled clinical trial evaluating the impact of 4CMenB or MenB-fHbp vaccination on the pharyngeal carriage of meningococci in adolescents.
Carr J; Plested E; Aley P; Camara S; Davis K; MacLennan JM; Gray S; Faust SN; Borrow R; Christensen H; Trotter C; Maiden MCJ; Finn A; Snape MD;
BMJ Open; 2020 Oct; 10(10):e037358. PubMed ID: 33093030
[TBL] [Abstract][Full Text] [Related]
7. 4CMenB journey to the 10-year anniversary and beyond.
Abitbol V; Martinón-Torres F; Taha MK; Nolan T; Muzzi A; Bambini S; Borrow R; Toneatto D; Serino L; Rappuoli R; Pizza M
Hum Vaccin Immunother; 2024 Dec; 20(1):2357924. PubMed ID: 38976659
[TBL] [Abstract][Full Text] [Related]
8. The cost-of-illness for invasive meningococcal disease caused by serogroup B Neisseria meningitidis (MenB) in Germany.
Scholz S; Koerber F; Meszaros K; Fassbender RM; Ultsch B; Welte RR; Greiner W
Vaccine; 2019 Mar; 37(12):1692-1701. PubMed ID: 30661834
[TBL] [Abstract][Full Text] [Related]
9. Culture-Confirmed Invasive Meningococcal Disease in Canada, 2010 to 2014: Characterization of Serogroup B
Tsang RSW; Law DKS; De Paola R; Giuliani M; Stella M; Zhou J; Deng S; Boccadifuoco G; Giuliani MM; Serino L
mSphere; 2020 Mar; 5(2):. PubMed ID: 32132156
[TBL] [Abstract][Full Text] [Related]
10. Potential Coverage of the 4CMenB Vaccine against Invasive Serogroup B
Mulhall RM; Bennett D; Cunney R; Borrow R; Lucidarme J; Findlow J; Jolley KA; Bray J; Maiden MCJ; Moschioni M; Serino L; Stella M; Medini D
mSphere; 2018 Aug; 3(4):. PubMed ID: 30135218
[No Abstract] [Full Text] [Related]
11. Cost of illness of invasive meningococcal disease caused by serogroup B Neisseria meningitidis in Spain.
Ivanova-Markova Y; González-Domínguez A; Hidalgo A; Sánchez R; García-Agua N; García-Ruiz AJ; Amanda Vallejo-Aparicio L; García A; Rodriguez R; de Gomensoro E; Gonzalez-Inchausti MDC; Shen J; Begum N; Tafalla M
Vaccine; 2021 Dec; 39(52):7646-7654. PubMed ID: 34794819
[TBL] [Abstract][Full Text] [Related]
12. Epidemiological impact and cost-effectiveness of universal vaccination with Bexsero(®) to reduce meningococcal group B disease in Germany.
Christensen H; Irving T; Koch J; Trotter CL; Ultsch B; Weidemann F; Wichmann O; Hellenbrand W
Vaccine; 2016 Jun; 34(29):3412-9. PubMed ID: 27109566
[TBL] [Abstract][Full Text] [Related]
13. Genomic Characterization of Invasive Meningococcal Serogroup B Isolates and Estimation of 4CMenB Vaccine Coverage in Finland.
Bodini M; Brozzi A; Giuliani M; Nohynek H; Vainio A; Kuusi M; De Paola R; Pizza M; Medini D; Toropainen M; Serino L; Muzzi A
mSphere; 2020 Sep; 5(5):. PubMed ID: 32938694
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in meningococcal B disease prevention: real-world evidence from 4CMenB vaccination.
Martinón-Torres F; Banzhoff A; Azzari C; De Wals P; Marlow R; Marshall H; Pizza M; Rappuoli R; Bekkat-Berkani R
J Infect; 2021 Jul; 83(1):17-26. PubMed ID: 33933528
[TBL] [Abstract][Full Text] [Related]
15. [Economic evaluation of the introduction of 4CMenB (Bexsero®) in the national vaccine schedule in Spain].
Ruiz-Montero R; Epstein D; Guzmán Herrador B; Espín Balbino J
Gac Sanit; 2020; 34(4):318-325. PubMed ID: 31776044
[TBL] [Abstract][Full Text] [Related]
16. Timing of meningococcal vaccination with 4CMenB (Bexsero®) in children with invasive meningococcal group B (MenB) disease in England.
Ladhani SN; Campbell H; Amin-Chowdhury Z; Lucidarme J; Borrow R; Ramsay ME
Vaccine; 2022 Mar; 40(10):1493-1498. PubMed ID: 35148913
[TBL] [Abstract][Full Text] [Related]
17. Multicomponent meningococcal serogroup B vaccination elicits cross-reactive immunity in infants against genetically diverse serogroup C, W and Y invasive disease isolates.
Biolchi A; De Angelis G; Moschioni M; Tomei S; Brunelli B; Giuliani M; Bambini S; Borrow R; Claus H; Gorla MCO; Hong E; Lemos APS; Lucidarme J; Taha MK; Vogel U; Comanducci M; Budroni S; Giuliani MM; Rappuoli R; Pizza M; Boucher P
Vaccine; 2020 Nov; 38(47):7542-7550. PubMed ID: 33036804
[TBL] [Abstract][Full Text] [Related]
18. Real-world implementation of 4-component meningococcal serogroup B vaccine (4CMenB): implications for clinical practices.
Sohn WY; Tahrat H; Novy P; Bekkat-Berkani R
Expert Rev Vaccines; 2022 Mar; 21(3):325-335. PubMed ID: 35068299
[TBL] [Abstract][Full Text] [Related]
19. Four-Component Recombinant Protein-Based Vaccine Effectiveness Against Serogroup B Meningococcal Disease in Italy.
Lodi L; Barbati F; Amicizia D; Baldo V; Barbui AM; Bondi A; Costantino C; Da Dalt L; Ferrara L; Fortunato F; Guarnieri V; Icardi G; Indolfi G; Martinelli D; Martini M; Moriondo M; Nieddu F; Peroni DG; Prato R; Ricci S; Russo F; Tirelli F; Vitale F; Ladhani SN; Azzari C;
JAMA Netw Open; 2023 Aug; 6(8):e2329678. PubMed ID: 37594762
[TBL] [Abstract][Full Text] [Related]
20. Modelling the impact of 4CMenB and MenACWY meningococcal combined vaccination strategies including potential 4CMenB cross-protection: An application to England.
Beck E; Klint J; Garcia S; Abbing V; Abitbol V; Akerborg O; Argante L; Bekkat-Berkani R; Hogea C; Neine M; Vadivelu K; Whelan J; Meszaros K
Vaccine; 2020 Nov; 38(47):7558-7568. PubMed ID: 32807531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
